HRP20190062T1 - Fragmenti neaciliranog grelina za uporabu u liječenju prader-willi sindroma - Google Patents

Fragmenti neaciliranog grelina za uporabu u liječenju prader-willi sindroma

Info

Publication number
HRP20190062T1
HRP20190062T1 HRP20190062TT HRP20190062T HRP20190062T1 HR P20190062 T1 HRP20190062 T1 HR P20190062T1 HR P20190062T T HRP20190062T T HR P20190062TT HR P20190062 T HRP20190062 T HR P20190062T HR P20190062 T1 HRP20190062 T1 HR P20190062T1
Authority
HR
Croatia
Prior art keywords
greeline
prader
acylated
fragments
treatment
Prior art date
Application number
HRP20190062TT
Other languages
English (en)
Croatian (hr)
Inventor
Aart Jan Van Der Lely
Thierry Abribat
Original Assignee
Millendo Therapeutics Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millendo Therapeutics Sas filed Critical Millendo Therapeutics Sas
Publication of HRP20190062T1 publication Critical patent/HRP20190062T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
HRP20190062TT 2011-12-15 2012-12-14 Fragmenti neaciliranog grelina za uporabu u liječenju prader-willi sindroma HRP20190062T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161576217P 2011-12-15 2011-12-15
EP12829142.4A EP2790721B8 (en) 2011-12-15 2012-12-14 Fragments of unacylated ghrelin for use in the treatment of prader-willi syndrome
PCT/IB2012/002867 WO2013088241A1 (en) 2011-12-15 2012-12-14 Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin

Publications (1)

Publication Number Publication Date
HRP20190062T1 true HRP20190062T1 (hr) 2019-03-08

Family

ID=47780096

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190062TT HRP20190062T1 (hr) 2011-12-15 2012-12-14 Fragmenti neaciliranog grelina za uporabu u liječenju prader-willi sindroma

Country Status (16)

Country Link
US (2) US20140336109A1 (enExample)
EP (1) EP2790721B8 (enExample)
JP (1) JP6031121B2 (enExample)
CA (1) CA2857276A1 (enExample)
CY (1) CY1121296T1 (enExample)
DK (1) DK2790721T3 (enExample)
ES (1) ES2705499T3 (enExample)
HR (1) HRP20190062T1 (enExample)
HU (1) HUE042102T2 (enExample)
LT (1) LT2790721T (enExample)
PL (1) PL2790721T3 (enExample)
PT (1) PT2790721T (enExample)
RS (1) RS58237B1 (enExample)
SI (1) SI2790721T1 (enExample)
TR (1) TR201900438T4 (enExample)
WO (1) WO2013088241A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2790721T (lt) 2011-12-15 2019-02-11 Millendo Therapeutics Sas Neacilinto grelino fragmentai, skirti naudoti preiderio-vilio sindromo gydymui
WO2014203074A2 (en) 2013-06-21 2014-12-24 Alize Pharma Sas Use of unacylated ghrelin, fragments and analogs thereof as antioxidant
EP3193939A4 (en) * 2014-09-17 2018-10-24 The Regents of The University of California Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase
KR102323613B1 (ko) 2014-11-14 2021-11-09 에센셜리스 인코포레이티드 프라더-윌리 증후군 또는 스미스-마제니스 증후군을 가지는 대상체를 치료하는 방법
US10053693B2 (en) 2016-01-19 2018-08-21 Mubin I. Syed Method for controlling obesity using minimally invasive means

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271198B1 (en) 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
US6627729B1 (en) 1997-03-24 2003-09-30 Zymogenetics, Inc. TML peptides
WO2000023469A2 (en) 1998-10-16 2000-04-27 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
AU2001228325A1 (en) 2000-02-01 2001-08-14 Novo-Nordisk A/S Use of compounds for the regulation of food intake
EP1286697A2 (en) 2000-05-17 2003-03-05 Eli Lilly And Company Method for selectively inhibiting ghrelin action
CA2411667A1 (en) 2000-05-30 2001-12-06 Merck & Co. Inc. Ghrelin analogs
WO2002060477A1 (en) 2001-01-31 2002-08-08 Human Genome Sciences, Inc. Scaffolded fusion polypeptides, compositions for making the same and methods of using the same
JP4493913B2 (ja) 2001-01-31 2010-06-30 中外製薬株式会社 低栄養症状疾患治療剤
CA2470235C (en) 2001-12-18 2012-02-07 Theratechnologies Inc. Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
US7666833B2 (en) 2001-12-18 2010-02-23 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
WO2003051389A2 (en) 2001-12-18 2003-06-26 Theratechnologies Inc. Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
JP5000848B2 (ja) 2002-05-21 2012-08-15 第一三共株式会社 グレリン含有医薬組成物
CA2543507C (en) 2003-10-24 2012-05-01 Theratechnologies Inc. Use of ghrelin and unacylated ghrelin compositions in insulin-related disease conditions
WO2006045319A2 (en) 2004-10-27 2006-05-04 Gastrotech Pharma A/S Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure
US8653022B2 (en) 2006-03-28 2014-02-18 Liat Mintz Use of ghrelin splice variant for treating hypercholesterolemia and/or high cholesterol and/or high cholesterol complication and/or lipemia and/or lipemia complication and/or coronary heart disease and/or weight management and/or diabetes and/or hyperglycemia
US8318664B2 (en) * 2007-05-31 2012-11-27 Alize Pharma Sas Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity
ES2538111T3 (es) 2007-05-31 2015-06-17 Alizé Pharma SAS Grelina no acilada como agente terapéutico en el tratamiento de trastornos metabólicos
EP2067481A1 (en) * 2007-12-03 2009-06-10 Charité-Universitätsmedizin Berlin Therapeutic use of desacyl ghrelin
US8476408B2 (en) * 2008-06-13 2013-07-02 Alize Pharma Sas Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
LT2790721T (lt) 2011-12-15 2019-02-11 Millendo Therapeutics Sas Neacilinto grelino fragmentai, skirti naudoti preiderio-vilio sindromo gydymui

Also Published As

Publication number Publication date
PL2790721T3 (pl) 2019-05-31
JP6031121B2 (ja) 2016-11-24
US20140336109A1 (en) 2014-11-13
DK2790721T3 (en) 2019-02-04
EP2790721B8 (en) 2018-11-28
EP2790721A1 (en) 2014-10-22
PT2790721T (pt) 2019-01-24
SI2790721T1 (sl) 2019-03-29
ES2705499T3 (es) 2019-03-25
HUE042102T2 (hu) 2019-06-28
CY1121296T1 (el) 2020-05-29
RS58237B1 (sr) 2019-03-29
TR201900438T4 (tr) 2019-02-21
JP2015501832A (ja) 2015-01-19
LT2790721T (lt) 2019-02-11
CA2857276A1 (en) 2013-06-20
WO2013088241A1 (en) 2013-06-20
US20130157936A1 (en) 2013-06-20
EP2790721B1 (en) 2018-10-17
US9550821B2 (en) 2017-01-24

Similar Documents

Publication Publication Date Title
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
BR112013029782A2 (pt) copo de bebida e conjunto de copo de bebida
PL3199024T3 (pl) Zastosowanie kompozycji cyklodekstryny i stosowne sposoby
SI2729151T1 (sl) Farmacevtski sestavek, postopki za zdravljenje in njihove uporabe
ZA201400562B (en) Axmi205 variant proteins and methods for their use
EP2716169A4 (en) BEVERAGE COMPOSITION
DK3760707T3 (da) Fibroblaster til anvendelse i behandling af diskusdegeneration
IL233111A0 (en) Preparations for the treatment of inflammation
ITBO20120529A1 (it) Apparecchio di trattamento alimentare
IL230698A0 (en) Use of preparations containing crizotinib to treat cancer
BR112013034055A2 (pt) alcaftadina para uso no tratamento de urticária
PT2750709T (pt) Tratamento da caquexia
DK2783256T3 (da) Terapeutiske briller
HRP20180687T1 (hr) Kompozicije i metode za liječenje celijakije spru
ZA201306613B (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
EP2750811A4 (en) CLEANING METHOD AND APPARATUS
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
EP2790721B8 (en) Fragments of unacylated ghrelin for use in the treatment of prader-willi syndrome
HRP20180011T1 (hr) Spojevi za uporabu u liječenju filariaza
IL230746A0 (en) 2-aldh inhibitors in the treatment of addiction
PH12014501052A1 (en) Methods and compositions for the treatment of diabetes and related symptoms
EP2775863C0 (en) Multi-flavored beverage
HRP20150141T1 (xx) Upotreba nifuratela u lijeäśenju infekcija uzrokovanih klostridijima
DE112011104700A5 (de) Schleifverfahren
HK1189818A (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme